Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study

Journal of B.U.ON.

Volumn 18, Issue 1, 2013, Pages 195-201

  Daniilidou, K ^a   Frangou Plemenou, M ^a   Grammatikakis, J ^b   Grigoriou, O ^a   Vitoratos, N ^a   Kondi Pafiti, Agatha ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Endometrial adenocarcinoma; Endometrioid adenocarcinoma; p53; PTEN; Serous papillary adenocarcinoma

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM POLYP; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PERITONEUM METASTASIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; CARCINOMA, PAPILLARY; CHI-SQUARE DISTRIBUTION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879028882     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Robert J, Kurman L, Ellenson H, Ronnett BM (Eds): Blaustein's Pathology of the Female Genital System (6th Edn). Springer, New York, 2011, Ch.9, pp 394-398.
2. Albertini AF, Devouassoux-Shisheboran M, Genestie C. Pathology of endometrioid carcinoma. Bull Cancer 2012; 99: 1-12.
3. Bokhman V. Two pathogenetic types of endometrial carcinoma. Gynecolog Oncol 1983; 15:10-17,
4. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009; 16:8-13.
5. Boruban C, Altundag K, Kilic GS, Blankstein J. From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures. Eur J Cancer Prev 2008;17:133-138. (Pubitemid 351301624)
6. Kaku T, Kamura T, Hirakawa T et al. Endometrial carcinoma associated with hyperplasia-immunohistochemical study of angiogenesis and p53 expression. Gynecol Oncol 1999;72:51-55. (Pubitemid 29045446)
7. Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 2012;31:48-56.
8. Merritt MA, Cramer DW. Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark 2011;9:287-305.
9. Mutter GL. PTEN, a protean tumor suppressor. Am J Pathol 2001;158:1895-1898. (Pubitemid 32545170)
10. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers, J Natl Cancer Inst 2000; 92:924-930.
11. Zheng W, Cao P, Zheng M, Kramer EE, Godwin TA. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996;61:167-174. (Pubitemid 26145719)
12. Lee E-J, Kim T-J, Kim D S et al. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol Oncol 2010;116:533-538.
13. Lax SF, Kendall B, Tashiro H, Slebos RJC, Ellenson LH. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000; 88:814-824. (Pubitemid 30091101)
14. Demopoulos RI, Mesia AF, Mittal K, Vamvakas E. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis. Int J Gynecol Pathol. 1999;18:233-237. (Pubitemid 29306980)
15. Kim TH, Wang J, Lee KY et al. The synergistic effect of conditional PTEN loss and oncogenic K-ras mutation on endometrial cancer development occurs via decreased progesterone receptor action. J Oncol 2010; doi 10.1155/2010/139087.
16. Kurose K, Zhou X-P, Araki T, Cannistra SA, Maher ER, Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 2001;158:2097-2106. (Pubitemid 32545195)
17. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27:5497-5510.
18. Soslow RA, Bissonnette JP, Wilton A et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: Similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007; 31: 979-987. (Pubitemid 47012293)
19. Alkushi A, Köbel M, Kalloger SE, Gilks CB. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol 2010;29:343-350.
20. Maxwell GL, Risinger JI, Gumbs C et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias, Cancer Res 1998;58:2500-2503. (Pubitemid 28275414)
21. Koul R. Willen P-O, Bendahl M, Nilbert M, Borg A. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 2002;94:2369-2379.
22. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997;150:177-185. (Pubitemid 27027108)